In a nutshell This study aimed to investigate if asciminib was effective in patients with chronic myeloid leukemia who had resistance or unacceptable side effects to other tyrosine kinase inhibitors. This study concluded that asciminib showed promise in these patients. Some background Asciminib is a...
Read MoreType of leukemia-Chronic Myeloid Leukemia (CML) Posts on Medivizor
What factors predict blood-related side effects of tyrosine kinase inhibitors in chronic myeloid leukemia?
In a nutshell This study aimed to investigate the occurrence of hematological (blood-related) side effects in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. This study concluded that bone marrow fibrosis at diagnosis was a predictor of hematological side effects from tyrosine...
Read MorePonatinib treatment for leukemia – expert recommendation consensus
In a nutshell This review aimed to look at ponatinib treatment for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia with a focus on cardiovascular management. This review concluded that ponatinib can lead to increased cardiovascular...
Read MoreLate anemia in elderly patients with newly diagnosed chronic myeloid leukemia treated with imatinib
In a nutshell This study aimed to investigate the occurrence of late chronic anemia in older patients with chronic myeloid leukemia treated with imatinib. This study concluded that late chronic anemia is common in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibitor (TKI). This is...
Read MoreIs stopping nilotinib treatment safe in patients with chronic myelogenous leukemia that have achieved a stable response?
In a nutshell This study aimed to investigate the safety and effectiveness of stopping nilotinib treatment in patients with chronic-phase chronic myelogenous leukemia. This study concluded that stopping nilotinib after two years of consolidation treatment was safe and effective. Some background...
Read MoreComparing frontline treatments for chronic phase chronic myeloid leukemia
In a nutshell This study aimed to compare the safety and effectiveness of front-line treatments for patients with newly diagnosed chronic phase chronic myeloid leukemia. This study concluded that nilotinib, dasatinib, and radotinib are the safest and most effective treatments for these...
Read MoreSearching for patients with chronic myeloid leukemia to try a new combination of targeted treatments.
In a nutshell This study is searching for patients with chronic myeloid leukemia (CML) to try a new drug ruxolitinib (NSC-752295) with BCR-ABL Tyrosine Kinase Inhibitors. The main outcome that will be measured is the rate of significant reduction of the BCR-ABL marker. This trial is recruiting across the United States. The details BCR-ABL is a protein...
Read MoreKidney problems in patients being treated for chronic myeloid leukemia.
In a nutshell This study looked at the risk of kidney damage in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitor (TKI) therapy. Researchers found that imatinib (Gleevec) was linked with greater damage to the kidney compared to nilotinib (Tasigna) or dasatinib (Sprycel) in these patients. Some background...
Read MoreLooking for patients with Ph+ or BCR-ABL+ acute lymphoblastic leukemia to test a treatment combination
In a nutshell This phase 2 trial is evaluating the effectiveness of ponatinib (Iclusig) plus chemotherapy for patients with acute lymphoblastic leukemia (ALL) that is positive for the Philadelphia chromosome (Ph+) or the BCR-ABL gene (BCR-ABL+). The main outcome to be measured will be the number of patients who respond to treatment. This study is...
Read MoreLong term outcomes of imatinib treatment for chronic myeloid leukemia
In a nutshell This study aimed to investigate the long-term outcomes of imatinib treatment in patients with CML. This study concluded that imatinib is safe and effective for long periods of use. Some background Imatinib (Gleevec) is a tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia (CML). TKIs...
Read MoreEvaluating first-line imatinib for elderly patients with chronic myeloid leukemia
In a nutshell This study compared the effects of age and treatment dose for imatinib (Gleevec) in elderly versus younger patients with chronic myeloid leukemia (CML). This study concluded older patients had similar responses to therapy compared to younger patients. Some background Tyrosine kinase (TK) inhibitors are the standard therapy for chronic...
Read MoreEvaluating the risk of heart side effects of bosutinib in patients with chronic myeloid leukemia
In a nutshell This study evaluated the effects of bosutinib (Bosulif) on the heart in patients with chronic myeloid leukemia (CML). This study concluded that bosutinib was associated with heart-related side effects, particularly in high-risk patients. Some background Previous studies have shown that bosutinib is effective and well-tolerated. However,...
Read More
